Article
Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com
All News
Article
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - and the top 5 reasons to attend RheumNow Live 2026, which is one week away.
Article
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.
Dr. John Cush
Tweet
REcently published SMILE study looked at the potential of HCQ (vs PBO) to prevent SLE in at risk people. Had to be ANA+ and 1-2 SLICC criteria at entry. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/s4Mzoec5ga
Dr. John Cush
Tweet
Factors that may augment future development of SLE - includes Vitamin D levels, poor sleep, EBV reactivation & social determinants of health. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/2J1JBjeXKU
Dr. John Cush
Tweet
FDA has announced "Breakthrough Designation" for 3 drugs + 1 test being developed:
** Biogen: litifilimab (targets dendritic cells) for cutaneous lupus
** Novartis: Ianalumab (BAFF blockade) for Sjogrens
** J&J: Nipocaiimab (FcRn) for Sjogrens
** Encarta: pocket Lyme test https://t.co/RMKg14rejq
Dr. John Cush
Tweet
FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj
Dr. John Cush
Tweet
NEXT STEPS: Karp and investigators are engaged in the MONA LISA study - Using smile Data and biospeciments – they intend to look for biomarkers that may better predict the future development of SLE Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/acZD1kmNhq
Dr. John Cush
Tweet
The challenge may be that lupus has multiple endotypes with variable rates of progression/trajectories. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/BA4KRKebIv
Dr. John Cush
Tweet
SMILE enrollment hampered by COVID - yet failed to show a protective effect for HCQ in preventing SLE. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/GImHpycbgO
Dr. John Cush
Tweet
REcently published SMILE study looked at the potential of HCQ (vs PBO) to prevent SLE in at risk people. Had to be ANA+ and 1-2 SLICC criteria at entry. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/4FY0kOLdRT
Dr. John Cush
Tweet
Factors that may augment future development of SLE - includes Vitamin D levels, poor sleep, EBV reactivation & social determinants of health. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/e3TKATcxXB
Dr. John Cush
Tweet
Only a subset of incomplete lupus (ILE) will progress to SLE - betw 1 in 10 and 1 in 5. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/oo40Dumk4I
Dr. John Cush
Tweet
Can you Prevent SLE? Dr. David Karp lecturing at UTSW Showing that autoantibodies exist long before the onset of SLE @drdavidkarp @utswrheum https://t.co/zPAYbSlIBS
Dr. John Cush
Tweet
FDA has announced "Breakthrough Designation" for 3 drugs + 1 test being developed:
** Biogen: litifilimab (targets dendritic cells) for cutaneous lupus
** Novartis: Ianalumab (BAFF blockade) for Sjogrens
** J&J: Nipocaiimab (FcRn) for Sjogrens
** Encarta: pocket Lyme test https://t.co/zODOTWyqP8
Dr. John Cush
Tweet
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/P4dCVkoPCH
Dr. John Cush
Tweet
Remission? Single center study of 100 RA, 100 SLE pts assessed by SLEDAI-2K, SDAI, VAS. Remission/LDA found in 88% of 392 SLE visits & 91% of 389 RA visits(p=NS). Remission was more common in SLE vs RA (79% vs 69%; p= 0.0018). https://t.co/ZPRrYQMsCT
Dr. John Cush
Tweet
Japanese nationwide survey of 1943 RMD pts taking Azathioprine (AZA) 34% had adverse events: hepatobiliary (149%), GI (10%), blood/lymphatic (9%), infections (5%), & skin (2.4%). AEs lead to 71% D/C AZA. Serious AEs (Gr ≥3) higher w/ older (OR 2.5), & SLE (OR 2.3) https://t.co/lVNYVQATfx
Dr. John Cush
Tweet
Lupus Foundation announced today that US House of Representatives have approved $27 Million in Funding for Lupus Programs in 2026 w/ fund available from (CDC), OMH, & DoD. Funding increased 40% @ CDC, 33% @OMH, & $415 million @ National Institutes of Health https://t.co/ENcykcW7yA
Dr. John Cush
Tweet
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/snAVErShjK
